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harvest and hematological relapse was to long (median, 71
days). In ﬁve of these patients, DNAwas available at the time
of the last sample harvest before relapse and showed a
complete donor chimerism. In two patients, we diagnosed a
molecular relapse using WT1 gene expression. At that time,
both children revealed a complete donor chimerism. In both
patients, long-term molecular remission was achieved by
immunotherapy. In conclusion, quantitative analysis of WT1
gene expression is a valuable tool for monitoring of MRD
before and after HSCT. This approach is very useful for early
diagnosis and treatment of molecular relapse after HSCT.
MRD measurement using WT1 gene expression is more
sensitive for the detection of impending relapse than the
analysis of chimerism.
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Adult umbilical cord blood (UCB) transplant has emerged as
an important option for patients lacking matched related
(MRD) and matched unrelated donors (MUD). Numerous
studies have demonstrated comparable overall survival (OS)
between these donor sources as well as decreased classic
chronic GVHD (cGVHD) following UCB transplantation as
compared to MUD. We compared cGVHD incidence and
immunosuppression burden in consecutive patients under-
going UCB (n¼29) versus peripheral blood MUD transplant
(n¼51) at our center between June 2009 and February 2013.
NIH consensus criteria were used to grade cGVHD. Among
UCB patients, median age at transplant was 49 (range 22-71)
versus 55 (range 18-72) among MUDs. Twelve UCB patients
underwent myeloablative conditioning and 17 patients un-
derwent non-myeloablative (NMA) conditioning for acute
leukemia (n¼17), MDS (n¼5), CLL (n¼2), NHL (n¼4), and CML
(n¼1).GVHDprophylaxiswasCSAandMMF. Forty-eightMUD
patients were 10/10 matched and three patients were 8/8
matched (DQ mismatched). Seventeen patients underwent
myeloablative conditioning (TAC/MTX GVHD prophylaxis)
and 34 patients underwent NMA conditioning (TAC/MMF
GVHD prophylaxis) for acute leukemia (n¼19), NHL (n¼15),MDS (n¼6), CLL (n¼4), Other (n¼6). At two years post-
transplant, cumulative incidence (CI) of moderate to severe
cGVHD was 30% following MUD versus 7% following UCB
(p¼0.02). Among patients not experiencing competing risks
of relapse or transplant relatedmortality (TRM) prior to onset
of cGVHD, median time to being off immunosuppressionwas
307 days among UCB patients (n¼15) versus not reached
among MUD patients (n¼33) (p<0.001). Among 15 UCB pa-
tients, one patient remains on immunosuppression (227 days
post-transplant). Twopatients restarted immunosuppression
due to recrudescent symptoms, but both patients subse-
quently tapered again and remain off immunosuppression.
All 15 patients remain alive. Among 33 MUD patients, seven
patients stopped immunosuppression and four subsequently
restarted for recrudescent GVHD symptoms. All four remain
on immunosuppressive therapy. Five of the 33 patients sub-
sequently died of complications related toGVHD. One year OS
is not signiﬁcantly different between UCB and MUD patients
(65% UCB versus 67% MUD). Cumulative incidence of relapse
and TRM are also non-signiﬁcant comparing UCB and MUD
patients (one year CI relapse 21% UCB versus 17% MURD, CI
TRM 11% UCB versus 17% MUD). These data conﬁrm the low
incidence of classic cGVHD following CBT. We demonstrate a
markedly lower immunosuppression burden following UCB
versus MUD transplant without decreased OS, increased
relapse, or TRM. Combined with the rapid availability of UCB,
this ﬁnding has led our center tomove primarily toUCBwhen
a MRD is not available. Assessment of early and late costs of
transplant using this donor selection approach is ongoing.20
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Cause-speciﬁc death (CSD) due to transplant-related com-
plications (TRM) after URD-HCT is often multi-factorial.
Consensus adjudication panels (CP), commonly used in
clinical trials, are rarely used in observational research. Given
the risk of endpoint misclassiﬁcation due to CSD complexity
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uncover misclassiﬁcations that could cause confounding ef-
fects in a GWAS. A CP for CSD was developed, including 2
adult BMT physicians (MP, PLM), a pediatric oncologist (KO),
and BMTepidemiologist (TH). A genetic epidemiologist (LSC)
and statisticians (LP, DT, XZ) observed the CP. The training
cohort includes 2,609 10/10 HLA-matched T-replete mye-
loablative and reduced intensity URD-HCT patients treated
2000 to 2008 for AML, ALL or MDS, reported to the Center for
International Blood and Marrow Transplant Research
(CIBMTR) by 151 transplant centers (TCs) with banked
recipient and donor samples; 1116 died 1-yr post-URD-
HCT. The CP held 3 sessions at the CIBMTR and weekly
teleconferences over 8 months. Consensus was reached by
reviewing clinical data summaries, autopsy reports, error
corrections and source documentation. Both internal
(random re-review of 11 cases) and external validity (sepa-
rate CP review of 21 cases) weremeasured. Of 1116 deaths, 99
(9%) needed additional information from the TC; 75/99 (76%)
of data queries were resolved after TC response, and 24/99
(24%) were re-reviewed by the CP for ﬁnal resolution. Several
agreement measures were generated to assess concordance
on CSD between TC/CP for all cases, and stratiﬁed by gender,
age, disease, disease status and year of URD-HCT. Logistic
models determined which covariates were associated with
odds of TC and CP CSD agreement and log-linear models
were used to assess dependencies between covariates and
TC/CP CSD. Of 465 cases reported by the TC as disease-related
death, the CP agreed with 99.6% (Table). Of 651 cases re-
ported by the TC as TRM, the CP agreed with 80% and adju-
dicated 130 as disease-related death, hence overall
agreement was 87.5%, kmax¼0.773. When considering CSD
(disease, GVHD, infection, organ failure, other) the overall
agreement was 72.8%, kmax¼0.786. Logistic models found
that TC and CP were about 2 fold less likely (p<.05) to agree
on CSD for ALL and MDS, when URD-HCT was in 2000-2003
(early in cohort) or when the patient was not in CR pre-URD-
HCT. Log-linear models showed the TC CSD, age and year of
URD-HCT were dependent, while the CP CSD and disease
status were dependent. While the TC and CP have good
agreement, the CP’s systematic review of cases eliminated a
cohort effect and dependencies between CSD and patient
characteristics. In analyses of transplant-speciﬁc failure, CPs
are a necessary and worthwhile component of genetic and
translational studies correlating outcomes with patient and
transplant-related characteristics.
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Background: Adenovirus is an important cause of viral
mortality in allogeneic hematopoietic stem cell trans-
plantation. T-cell depletion (TCD) and the use of cord blood
(CB) as a stem cell source are established risk factors for ADV
viremia. However, rates and outcomes of ADV are not well
established in thesepopulations.Weprospectivelymonitored
104 adult recipients of TCDor CB allografts by qPCR for ADV to
determine the rates of ADV viremia and disease to determine
the utility of PCR surveillance in these high-risk patients.
Methods: This was a prospective observational study of
adults transplanted 3/21/12-5/30/13 for treatment of hema-
tologic malignancies at a single center. TCD was performed
using CliniMacs CD34+ cell selection and all CB trans-
plantation (CBT) recipients received double-unit grafts. Pa-
tients were monitored for ADV by whole blood PCR assay
(Viracor-IBT Laboratories) from 14 to at least 100 days post-
transplant. ADV viremia was deﬁned as  1 PCR positive (
lower limit detection). ADV disease was deﬁned per Euro-
pean Group for Bone Marrow Transplantation guidelines.
Treatment for ADV viremia was at the clinician’s discretion.
Results: 104 patients (median age 53 years, range 22-71)were
transplanted including 73 (70%) TCD and 31 (30%) CB trans-
plants. Patients received myeloablative, reduced-intensity, or
non-myeloablative conditioning. 14 patients (8 TCD and 6 CBT
recipients,13%of cohort) hadADVviremia at amedianonsetof
+73 days (range 12-119) and with a median viral load at ﬁrst
detection of 900 copies/mL (range 190-29,100). The median
maximal viral loadwas 153,900 copies/mL. Five patients (5% of
total cohort, 38%of viremic patients) developedADVdisease (3
colitis, 1 cystitis, 1 colitis with cystitis) at a median of 12 days
from the ﬁrst positive qPCR. (Three CBT patients with ADV
disease received intravenous cidofovir and two TCD with ADV
colitis received CMX001). In addition, 5 patients (3 TCD and 2
CBT) were treated pre-emptively for ADV viremia (viral load>
10,000 copies/ml) with intravenous cidofovir. Overall, 3 (21%)
patients with ADV viremia died prior to day +100 (2 due to
toxoplasmosis and 1 due to ADV and CMV).
Conclusions:While ADV viremiawas infrequent (13%) in our
high-risk cohort, ADV disease developed in approximately
one-third of viremic patients. Overall, 10 out of 14 (76%)
patients with ADV viremia received anti-viral therapy (5 for
established disease and 5 pre-emptively). TCD and CB
transplant recipients with ADV viremia are at high risk for
disease. Thus, prospective surveillance is helpful for earlier
institution of anti-viral treatment.
